BACKGROUND: Inhibition of glycogen synthase kinase-3 (GSK-3) is thought to be a key feature in the therapeutic mechanism of several mood stabilizers; however, the role of GSK-3 in depressive behavior has not been determined. In these studies, we evaluated the antidepressive effect of L803-mts, a novel GSK-3 peptide inhibitor, in an animal model of depression, the mouse forced swimming test (FST). METHODS: Animals were intracerebroventricularly injected with L803-mts or with respective control peptide (cp) 1 hour, 3 hours, or 12 hours before their subjection to FST. RESULTS: Animals administered L803-mts showed reduced duration of immobility at all three time points tested, as compared with cp-treated animals. Expression levels of beta-catenin, the endogenous substrate of GSK-3, increased in the hippocampus of L803-mts-treated animals by 20%-50%, as compared with cp-treated animals. CONCLUSIONS: Our studies show, for the first time, that in-vivo inhibition of GSK-3 produces antidepressive-like behavior and suggest the potential of GSK-3 inhibitors as antidepressants.
BACKGROUND: Inhibition of glycogen synthase kinase-3 (GSK-3) is thought to be a key feature in the therapeutic mechanism of several mood stabilizers; however, the role of GSK-3 in depressive behavior has not been determined. In these studies, we evaluated the antidepressive effect of L803-mts, a novel GSK-3 peptide inhibitor, in an animal model of depression, the mouse forced swimming test (FST). METHODS: Animals were intracerebroventricularly injected with L803-mts or with respective control peptide (cp) 1 hour, 3 hours, or 12 hours before their subjection to FST. RESULTS: Animals administered L803-mts showed reduced duration of immobility at all three time points tested, as compared with cp-treated animals. Expression levels of beta-catenin, the endogenous substrate of GSK-3, increased in the hippocampus of L803-mts-treated animals by 20%-50%, as compared with cp-treated animals. CONCLUSIONS: Our studies show, for the first time, that in-vivo inhibition of GSK-3 produces antidepressive-like behavior and suggest the potential of GSK-3 inhibitors as antidepressants.
Authors: Jing Liu; Ming Guo; Di Zhang; Shao-Ying Cheng; Meilian Liu; Jun Ding; Philipp E Scherer; Feng Liu; Xin-Yun Lu Journal: Proc Natl Acad Sci U S A Date: 2012-07-09 Impact factor: 11.205
Authors: Samuel R Mathias; Emma E M Knowles; Jack W Kent; D Reese McKay; Joanne E Curran; Marcio A A de Almeida; Thomas D Dyer; Harald H H Göring; Rene L Olvera; Ravi Duggirala; Peter T Fox; Laura Almasy; John Blangero; David C Glahn Journal: Hum Brain Mapp Date: 2015-10-20 Impact factor: 5.038
Authors: Priscila B Rosa; Luis E B Bettio; Vivian B Neis; Morgana Moretti; Isabel Werle; Rodrigo B Leal; Ana Lúcia S Rodrigues Journal: Purinergic Signal Date: 2019-11-25 Impact factor: 3.765
Authors: Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk Journal: Inflammopharmacology Date: 2012-01-24 Impact factor: 4.473
Authors: T Couroussé; A Bacq; C Belzung; B Guiard; L Balasse; F Louis; A-M Le Guisquet; A M Gardier; A H Schinkel; B Giros; S Gautron Journal: Mol Psychiatry Date: 2014-08-05 Impact factor: 15.992